Retigabine

瑞替加滨

Report date: 2024/02/02 20:04:50
NMEFirst In Class

Base Information

Drug NameRetigabine
Drug Alias Name依佐加滨retigabina瑞替滨retigabinum瑞替加宾碱 +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonistsKCNQ (Kv7) potassium channel agonists
TargetsGamma-aminobutyric acid A receptorKCNQ (Kv7) potassium channel
Therapy Area/IndicationsDepressive Disorder, MajorDepressive DisorderDepression +[13] 
Global Approved IndicationsSeizuresEpilepsy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2011/03/27
Country/TerritoryBelgiumBulgariaCanada +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcUcl University Clinics Of Mont-GodinneTianjin Chase Sun Pharmaceutical Co Ltd +[10] 
Active IndicationsSeizuresEpileptic SyndromesEpilepsy +[5] 
Inactive IndicationsDepressive Disorder, MajorDepressive DisorderDepression +[8] 

Other Information

ATC CodeN03AX21
Related LinksWikipediaDrugBankKEGG